https://prabadinews.com/
  • October 7, 2026
  • Last Update July 17, 2026 9:28 pm
  • United States of America

FDA Grants I-DXd Breakthrough Therapy Designation in Treatment of ES-SCLC

FDA Grants I-DXd Breakthrough Therapy Designation in Treatment of ES-SCLC

The action is significant for patients with extensive-stage small cell lung cancer (SCLC), a population with limited treatment options.

administrator

Related Articles